缪丽燕

姓名：缪丽燕

技术职称：教授

导师类别：博士生导师

所在学科：临床药学

Email：miaolysuzhou@163.com

简介：

缪丽燕，教授，主任药师，博士生导师，我校附属第一医院副院长，药物临床试验机构办主任，我校药物研究与转化交叉研究所所长，我校拉斯维加斯登录网站3133临床药学系主任。兼具临床和药学背景，专业主攻方向为个体化药物治疗与新药临床研究。

学习、工作经历：

1984.9-1989.7 苏州医学院医学系本科  学士学位

1989.9-1992.7 广州中山医科大学药理系硕士学位

1995.9-1998.7 苏州医学院附属第一医院心血管内科博士学位

1998.7-1999.9苏州医学院附属第一医院心血管内科实验室

1999.7-2002.7 美国密西西比医学中心博士后

2002.7-至今  我校附属第一医院药剂科、国家药物临床试验机构、副院长

主要研究方向

1. 个体化药物治疗

2. 同位素示踪与临床药理 

科研项目（2010年至今）:

1. 《基于同位素示踪技术的抗肿瘤药物临床评价技术平台的建设》，国家新药创制重大专项，1698.87万。主持

2. 《FXR-胆汁酸介导的吡嗪酰胺肝毒性新机制及临床意义》，国家自然科学基金（面上），2017年,55万。主持

3. 《新型循环肿瘤DNA基因突变检测技术平台的研发及其在临床肿瘤靶向治疗中应用评价》，江苏省科技厅临床医学科技专项，2015.1-2017.12，50万。主持

4. 《多中心PIVAS集中调配人员抗肿瘤药物职业暴露的评估》，卫生部医院管理研究所，2013.11-2015.11，60万。主持

5. 《新颖的RhoA蛋白GTP结合域竞争性小分子抑制剂的设计与合成及其抑制血管痉挛活性研究》，国家自然科学基金，2012.10，编号81202394，23万。第二

7. 《即时临床基因分型检测与临床个体化用药研究》江苏省卫生厅医学重点人才资助项目，2011.10，编号RC2011110，110万。主持

8. 《CES1A2基因多态性与PCI术患者氯吡格雷代谢及抗血小板活性相关性研究》国家自然科学基金 2011。主持

9. 《基本药物制度下药物合理使用的评价与研究》苏州市科技项目应用基础研究医疗卫生重点项目 2010-2012年 SYS201001，50万。主持

获奖情况（近五年）：

1. 2017, 华夏医学科技奖二等奖,血管狭窄性疾病治疗干预的创新和临床应用

2. 2016.12，江苏省科学技术奖三等奖，血管狭窄性疾病干预的创新与应用。

3. 2016.2，江苏省卫生计生委“十二五”科教兴卫工程优秀重点学科和人才表彰中授予“优秀医学重点人才”称号。

4. 2015.8，江苏省医学新技术引进奖二等奖，非线性混合效应模型建模技术用于造血干细胞移植患者免疫抑制剂临床个体化药物治疗。

5. 2015.4，江苏医学科技奖三等奖，个体化治疗技术与服务平台的建立及其在临床合理用药中的应用评价。

6. 2015，苏州市科技进步奖三等奖，新颖的RhoA蛋白小分子抑制剂的研制及其药理活性研究。

7. 2011年江苏省“六大人才高峰”培养对象。

8. 2012年江苏省新技术引进奖二等奖，即时基因检测技术在华法林临床个体化给药中的应用研究。

学术任职:

中国药理学会治疗药物监测研究专业委员会主委、中国药学会医院药学专业委员会副主委、江苏省医学会临床药学专业委员会主委、江苏省医院协会药事管理专业委员会主委、INRUD/中国中心组“个体化药物治疗组”组长。

杂志编委：

《中国药房》副主编、《中国医院用药评价与分析》副主编、《药物不良反应杂志》编委、《中国临床药学杂志》编委、《药学与临床研究杂志》编委、《中国医院药学杂志》编委等。

代表文章(近5年)：

[1] C. Xie, L. Xue, Y. Zhang, J. Zhu, L. Zhou, Y. Hang, X. Ding, B. Jiang, L. Miao, Comparison of the prediction performance of different warfarin dosing algorithms based on Chinese patients, Pharmacogenomics 21 (2020) 23-32.

[2] F. Xia, S. Ma, Y. Bian, D. Yu, W. Ma, M. Miao, C. Huang, L. Miao, A retrospective study of the correlation of in vitro chemosensitivity using ATP-TCA with patient clinical outcomes in acute myeloid leukemia, Cancer Chemother Pharmacol 85 (2020) 509-515.

[3] Y. Wang, D. Pan, C. Huang, B. Chen, M. Li, S. Zhou, L. Wang, M. Wu, X. Wang, Y. Bian, J. Yan, J. Liu, M. Yang, L. Miao, Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody, MAbs 12 (2020) 1748322.

[4] Y. Wang, H. Ni, S. Zhou, K. He, Y. Gao, W. Wu, M. Wu, Z. Wu, X. Qiu, Y. Zhou, B. Chen, D. Pan, C. Huang, M. Li, Y. Bian, M. Yang, L. Miao, J. Liu, Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity, Cancer Immunol Immunother (2020).

[5] X.Y. Wang, Y. Wang, Q. Wu, J.J. Liu, Y. Liu, D.H. Pan, W. Qi, L.Z. Wang, J.J. Yan, Y.P. Xu, G.J. Wang, L.Y. Miao, L. Yu, M. Yang, Feasibility study of (68)Ga-labeled CAR T cells for in vivo tracking using micro-positron emission tomography imaging, Acta Pharmacol Sin (2020).

[6] L. Wang, L. Liu, X. Liu, M. Xiang, L. Zhou, C. Huang, Z. Shen, L. Miao, The gut microbes, Enterococcus and Escherichia-Shigella, affect the responses of heart valve replacement patients to the anticoagulant warfarin, Pharmacol Res 159 (2020) 104979.

[7] X. Liu, L. Xue, H. Zhang, Q. Xu, S. Zhang, S. Ma, X. Ding, L. Liu, J. Dong, L. Qian, W. Xia, K. Jiang, C. Huang, L. Miao, Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects, Clin Drug Investig 40 (2020) 555-566.

[8] L. Liu, X. Li, C. Huang, Y. Bian, X. Liu, J. Cao, W. Qu, L. Miao, Bile acids, lipid and purine metabolism involved in hepatotoxicity of first-line anti-tuberculosis drugs, Expert Opin Drug Metab Toxicol 16 (2020) 527-537.

[9] K. Li, S. Ma, L. Miao, S. Fan, B. Pan, W. Zhang, W. Su, Y. Xiong, Z. Gu, L. Guo, Y. Sai, Absorption, Metabolism and Excretion of Surufatinib in Rats and Humans, Curr Drug Metab 21 (2020) 357-367.

[10] S. Huang, Q. Xu, L. Liu, Y. Bian, S. Zhang, C. Huang, L. Miao, Effect of Green Tea and (-)-Epigallocatechin Gallate on the Pharmacokinetics of Rosuvastatin, Curr Drug Metab 21 (2020) 471-478.

[11] C. Huang, F. Xia, L. Xue, L. Liu, Y. Bian, Z. Jin, L. Miao, Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3, Cancer Chemother Pharmacol 85 (2020) 433-441.

[12] X. Ding, R. Zhu, J. Wu, L. Xue, M. Gu, L. Miao, Early Adalimumab and Anti-Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients, Clin Transl Sci 13 (2020) 547-554.

[13] Y. Bian, H. Zhang, S. Ma, Y. Jiao, P. Yan, X. Liu, S. Ma, Y. Xiong, Z. Gu, Z. Yu, C. Huang, L. Miao, Mass balance, pharmacokinetics and pharmacodynamics of intravenous HSK3486, a novel anaesthetic, administered to healthy subjects, Br J Clin Pharmacol (2020).

[14] S. Zhang, Z. Chen, C. Huang, C. Ding, C. Li, J. Chen, J. Zhao, L. Miao, Ultrasensitive and quantitative detection of EGFR mutations in plasma samples from patients with non-small-cell lung cancer using a dual PNA clamping-mediated LNA-PNA PCR clamp, Analyst 144 (2019) 1718-1724.

[15] L. Yi, H. Zhang, J.W. Zhang, X.M. You, Z.Q. Ning, J. Yu, L.F. Qian, L.Y. Miao, Study on Drug-Drug Interactions Between Chiglitazar, a Novel PPAR Pan-Agonist, and Metformin Hydrochloride in Healthy Subjects, Clin Pharmacol Drug Dev 8 (2019) 934-941.

[16] L. Xue, Y. Zhang, C. Xie, L. Zhou, L. Liu, H. Zhang, L. Xu, H. Song, M. Lin, H. Qiu, J. Zhu, Y. Zhu, J. Zou, W. Zhuang, B. Xuan, Y. Chen, Y. Fan, D. Wu, Z. Shen, L. Miao, Relationship between warfarin dosage and international normalized ratio: a dose-response analysis and evaluation based on multicenter data, Eur J Clin Pharmacol 75 (2019) 785-794.

[17] L. Xue, W.J. Zhang, J.X. Tian, L.N. Liu, H.H. Yan, W.W. Zhang, X.L. Ding, J.J. Zhang, L.Y. Miao, Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients, Pharm Res 37 (2019) 15.

[18] J. Meng, X.Y. Liu, S. Ma, H. Zhang, S.D. Yu, Y.F. Zhang, M.X. Chen, X.Y. Zhu, Y. Liu, L. Yi, X.L. Ding, X.Y. Chen, L.Y. Miao, D.F. Zhong, Metabolism and disposition of pyrotinib in healthy male volunteers: covalent binding with human plasma protein, Acta Pharmacol Sin 40 (2019) 980-988.

[19] C. Huang, Z. Wang, L. Liu, X. Liu, J. Dong, Q. Xu, B. Zhang, L. Miao, Predicting the dopamine D2 receptor occupancy of ropinirole in rats using positron emission tomography and pharmacokinetic-pharmacodynamic modeling, Xenobiotica 49 (2019) 143-151.

[20] Z. Chen, S. Zhang, C. Li, C. Xu, J. Zhao, L. Miao, Comprehensive Evaluation of the Factors Affecting Plasma Circulating Cell-Free DNA Levels and Their Application in Diagnosing Nonsmall Cell Lung Cancer, Genet Test Mol Biomarkers 23 (2019) 270-276.

[21] X. Liu, C. Huang, L. Xue, Q. Xu, W. Xia, X. Li, L. Miao, Simultaneous determination of bentysrepinine (Y101) and its metabolites M8 and M9 in human plasma by UPLC-MS/MS and its application to a pharmacokinetic study, J Pharm Biomed Anal 150 (2018) 287-293.

[22] Y. Hang, Y. Chen, L. Xue, S. Sun, L. Liu, J. Gao, C. Xie, X. Zhang, J. Zhu, J. Jin, L. Miao, Evaluating biapenem dosage regimens in intensive care unit patients with Pseudomonas aeruginosa infections: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation, Int J Antimicrob Agents 51 (2018) 484-487.

[23] Z. Chen, S. Zhang, S. Ma, C. Li, C. Xu, Y. Shen, J. Zhao, L. Miao, Evaluation of the in vitro Chemosensitivity and Correlation with Clinical Outcomes in Lung Cancer using the ATP-TCA, Anticancer Agents Med Chem 18 (2018) 139-145.

[24] J. Cao, Y. Mi, C. Shi, Y. Bian, C. Huang, Z. Ye, L. Liu, L. Miao, First-line anti-tuberculosis drugs induce hepatotoxicity: A novel mechanism based on a urinary metabolomics platform, Biochem Biophys Res Commun 497 (2018) 485-491.

[25] Z. Yan, S. Ma, Y. Zhang, Ma, F. Wang, J. Li, L. Miao, The structure of a small GTPaseRhoA in complex with PDZRhoGEF and the inhibitor HL47, Biotechnol Lett 39 (2017) 745-750.

[26] L. Xue, N. Holford, L.Y. Miao, Response to R-warfarin anticoagulant effect, Br J Clin Pharmacol 83 (2017) 2305-2306.

[27] L. Xue, N. Holford, X.L. Ding, Z.Y. Shen, C.R. Huang, H. Zhang, J.J. Zhang, Z.N. Guo, C. Xie, L. Zhou, Z.Y. Chen, L.S. Liu, L.Y. Miao, Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients, Br J Clin Pharmacol 83 (2017) 823-835.

[28] L. Liu, C. Huang, Y. Bian, L. Miao, GC-MS based metabolomics of CSF and blood serum: Metabolic phenotype for a rat model of cefoperazone-induced disulfiram-like reaction, Biochem Biophys Res Commun 490 (2017) 1066-1073.

[29] J. Zhang, J. Bao, R. Wang, Z. Geng, Y. Chen, X. Liu, Y. Xie, L. Jiang, Y. Deng, G. Liu, R. Xu, L. Miao, A multicenter study of biological effects assessment of pharmacy workers occupationally exposed to antineoplastic drugs in Pharmacy Intravenous Admixture Services, J Hazard Mater 315 (2016) 86-92.

[30] Z. Guo, Y. Chen, X. Ding, C. Huang, L. Miao, Simultaneous determination of ambroxol and salbutamol in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study, Biomed Chromatogr 30 (2016) 1789-1795.